Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (23780)	5/24/2007 11:50:21 AM
From: Arthur Radley	Read Replies (2) \| Respond to of 52153

USA Today had article that added color to this issue. The article stated that Dr. Nissen fully admitted there was weakness to his review process. The article further pointed out that GSK had put the FDA on notice several years ago that they had data that showed a potential issue. But as for Nissen, the article pointed out that Takeda's drug was in the same class and that Nissen was running clinic trials on it(Actos). IMO this could be a conflict and take something away from his objectivity.